BioDelivery Sciences International (BDSI) Given Daily Media Sentiment Score of 0.11

News headlines about BioDelivery Sciences International (NASDAQ:BDSI) have been trending somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioDelivery Sciences International earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 48.1658255523914 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s rankings:

Shares of BioDelivery Sciences International traded down $0.02, reaching $2.88, during midday trading on Friday, according to 404,567 shares of the stock were exchanged, compared to its average volume of 289,636. The company has a market capitalization of $172.12 million, a P/E ratio of -7.37 and a beta of 0.38. The company has a debt-to-equity ratio of 35.82, a current ratio of 1.40 and a quick ratio of 1.13. BioDelivery Sciences International has a twelve month low of $1.70 and a twelve month high of $3.42.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. The business had revenue of $12.18 million during the quarter, compared to the consensus estimate of $12.44 million. BioDelivery Sciences International had a negative net margin of 103.01% and a negative return on equity of 502.11%. research analysts expect that BioDelivery Sciences International will post -0.67 EPS for the current year.

A number of research analysts have weighed in on BDSI shares. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 24th. Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Tuesday, June 5th. ValuEngine raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, HC Wainwright decreased their target price on shares of BioDelivery Sciences International from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Wednesday, May 23rd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. BioDelivery Sciences International has an average rating of “Buy” and an average target price of $4.13.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: Market Capitalization in the Stock Market

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with's FREE daily email newsletter.

Leave a Reply